Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
- SKINVIVE by JUVÉDERM® is now the first and only hyaluronic acid injectable approved to reduce horizontal neck lines caused by “tech-neck.1“
- This is the second FDA-approved indication for SKINVIVE by JUVÉDERM®, which has been approved since 2023 to improve skin smoothness of the cheeks in adults.1
IRVINE, Calif., June 16, 2026 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance in adults over the age of 21.1 With this approval, SKINVIVE by JUVÉDERM® is the first and only hyaluronic acid (HA) injectable indicated to reduce the appearance of neck wrinkles and help skin retain its natural moisture, leading to an improved neck appearance.1
Neck wrinkles may develop due to natural aging, sun damage, weight loss, or “tech-neck” caused by the head-down position used for phones, tablets, and books.1 SKINVIVE by JUVÉDERM® reduces neck lines formed by tech-neck by helping the skin retain its natural moisture, softness, and smoothness.1 Treatment with SKINVIVE by JUVÉDERM® is minimally invasive with little to no downtime and is administered using an ultrafine needle or cannula. The product contains a small amount of local anesthetic (lidocaine) to support patient comfort during treatment. Results last six months with optimal treatment.1,*
“The approval of SKINVIVE by JUVÉDERM® for horizontal neck wrinkles reflects Allergan Aesthetics’ commitment to developing science-driven innovations that address meaningful unmet aesthetic needs,” said Darin Messina, Ph.D., senior vice president, aesthetics R&D, AbbVie. “This approval expands our portfolio of lower face and neck treatment options and gives patients and aesthetic providers a first-of-its-kind treatment option for improving neck skin quality and reducing the appearance of neck lines.1,3,*”
In the randomized, multicenter, evaluator-blinded, controlled pivotal clinical study, 74.8% (78.5/105) of participants treated in the neck with SKINVIVE by JUVÉDERM® saw clinically significant (≥ 1 point) improvement on the validated 5-grade photonumeric Allergan Transverse Neck Lines Scale (ATNLS) at one month.2,† Most participants (66% or 64/97) maintained ≥ 1 point improvement in horizontal neck lines at six months.2 Participants who demonstrated improvement from baseline in overall score stayed high (≥78%) at all timepoints during the study.2
Participants in the clinical study reported experiencing adverse events (AEs) such as redness, bruising, tenderness, lumps/bumps, swelling, firmness, pain, discoloration, and itching at the injection sites, as reported in their electronic diaries.1 These AEs were usually mild (causing little discomfort and no effect on daily activities), did not require treatment, and resolved within two weeks.1 Severe AEs were experienced by less than 5% of participants (7/147 reporting AEs).1 These AEs were reported similarly or less frequently after touch-ups and repeat treatments.1
As with some novel products, the FDA has required that Allergan Aesthetics provide a training program for all interested providers. Successful completion of this training is necessary prior to purchase of and administration of SKINVIVE by JUVÉDERM®. Allergan Aesthetics anticipates that SKINVIVE by JUVÉDERM® for the improvement of neck appearance will be broadly commercially available later this year.
To learn more about SKINVIVE by JUVÉDERM® visit www.skinvive.com and follow @skinvive on Instagram.
*Optimal treatment with SKINVIVE by JUVÉDERM® may require an optional touch-up one month after initial treatment to achieve the desired aesthetic outcome and is dependent on patient need.1
†The safety and effectiveness of SKINVIVE by JUVÉDERM® neck treatment has not been studied in darker skin tone patients.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.